Literature DB >> 26314990

Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.

Natalie Artzi1,2, Abraham R Tzafriri3,4, Keith M Faucher5, Geoffrey Moodie5, Theresa Albergo5, Suzanne Conroy5, Scott Corbeil5, Paul Martakos5, Renu Virmani6, Elazer R Edelman1,7.   

Abstract

The long held assumption that sustained drug elution from stent coatings over weeks to months is imperative for clinical efficacy has limited the choice for stent coating materials. We developed and evaluated an omega-3 fatty acid (O3FA) based stent coating that is 85% absorbed and elutes 97% of its Sirolimus analog (Corolimus) load within 8d of implantation. O3FA coated stents sustained drug levels in porcine coronary arteries similarly to those achieved by slow-eluting durable coated Cypher Select Plus Stents and with significantly lower levels of granuloma formation and luminal stenosis. Computational modeling confirmed that diffusion and binding constants of Corolimus and Sirolimus are identical and explained that the sustained retention of Corolimus was facilitated by binding to high affinity intracellular receptors (FKBP12). First in man outcomes were positive-unlike Cypher stents where late lumen loss drops over 6 month, there was a stable effect without diminution in the presence of O3FA. These results speak to a new paradigm whereby the safety of drug eluting stents can be optimized through the use of resorbable biocompatible coating materials with resorption kinetics that coincide with the dissociation and tissue elimination of receptor-bound drug.

Entities:  

Keywords:  Computational modeling; Drug eluting stents; Sirolimus analogs

Mesh:

Substances:

Year:  2015        PMID: 26314990      PMCID: PMC4767594          DOI: 10.1007/s10439-015-1435-z

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  25 in total

Review 1.  Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.

Authors:  Robert S Schwartz; Elazer R Edelman; Andrew Carter; Nicolas Chronos; Campbell Rogers; Keith A Robinson; Ron Waksman; Judah Weinberger; Robert L Wilensky; Donald N Jensen; Bram D Zuckerman; Renu Virmani
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

2.  The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography.

Authors:  Jun Tanigawa; Peter Barlis; Konstantinos Dimopoulos; Miles Dalby; Philip Moore; Carlo Di Mario
Journal:  Int J Cardiol       Date:  2008-09-04       Impact factor: 4.164

3.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

Authors:  Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani
Journal:  J Am Coll Cardiol       Date:  2006-05-05       Impact factor: 24.094

4.  Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.

Authors:  Aloke V Finn; Frank D Kolodgie; Jan Harnek; L J Guerrero; Eduardo Acampado; Kirubel Tefera; Kristi Skorija; Deena K Weber; Herman K Gold; Renu Virmani
Journal:  Circulation       Date:  2005-07-05       Impact factor: 29.690

5.  Technique to control pH in vicinity of biodegrading PLA-PGA implants.

Authors:  C M Agrawal; K A Athanasiou
Journal:  J Biomed Mater Res       Date:  1997

6.  Endovascular stent design dictates experimental restenosis and thrombosis.

Authors:  C Rogers; E R Edelman
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

7.  Intramural delivery of Sirolimus prevents vascular remodeling following balloon injury.

Authors:  Michael Buerke; Markus Guckenbiehl; Hansjörg Schwertz; Ute Buerke; Michael Hilker; Herbert Platsch; Joachim Richert; Sabine Bomm; Guy A Zimmerman; Stephan Lindemann; Ursula Mueller-Werdan; Karl Werdan; Harald Darius; Andrew S Weyrich
Journal:  Biochim Biophys Acta       Date:  2006-05-19

8.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.

Authors:  D I Axel; W Kunert; C Göggelmann; M Oberhoff; C Herdeg; A Küttner; D H Wild; B R Brehm; R Riessen; G Köveker; K R Karsch
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

9.  Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months.

Authors:  D E Drachman; E R Edelman; P Seifert; A R Groothuis; D A Bornstein; K R Kamath; M Palasis; D Yang; S H Nott; C Rogers
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

10.  Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?

Authors:  Renu Virmani; Giulio Guagliumi; Andrew Farb; Giuseppe Musumeci; Niccolo Grieco; Teresio Motta; Laurian Mihalcsik; Maurizio Tespili; Orazio Valsecchi; Frank D Kolodgie
Journal:  Circulation       Date:  2004-01-26       Impact factor: 29.690

View more
  4 in total

Review 1.  Endovascular Drug Delivery and Drug Elution Systems: First Principles.

Authors:  Abraham Rami Tzafriri; Elazer Reuven Edelman
Journal:  Interv Cardiol Clin       Date:  2016-06-21

2.  Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics.

Authors:  Abraham R Tzafriri; Sahil A Parikh; Elazer R Edelman
Journal:  J Control Release       Date:  2019-08-17       Impact factor: 9.776

3.  How does the Nature of an Excipient and an Atheroma Influence Drug-Coated Balloon Therapy?

Authors:  Martin Lindsay Buist; Hwa Liang Leo; Karthic Anbalakan; Han Wei Toh; Hui Ying Ang
Journal:  Cardiovasc Eng Technol       Date:  2022-05-23       Impact factor: 2.495

Review 4.  Evolution of drug-eluting biomedical implants for sustained drug delivery.

Authors:  Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal:  Eur J Pharm Biopharm       Date:  2020-12-16       Impact factor: 5.589

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.